Zyne Tan

[DeBakey CV Education - World Class CV Training @DeBakeyCVedu]

Anti-inflammatory therapy (NSAID, colchicine, corticosteroid & IL-1 inhibitor) is cornerstone of treatment in inflammatory & transient forms

Constrictive Pericarditis & Effusive Constrictive Pericarditis-L El Harake, M Al-Kazaz, P Cremer
https://t.co/tRhUELYRxk #DeBakeyCVJournal

[Yonemoto N @nyonenyone]

Cancer and Cardiovascular Disease: Shared Risk Factors, Mechanisms, and Clinical Implications: JACC: CardioOncology State-of-the-Art Review | JACC: CardioOncology https://t.co/JjI8zpSs2k

[Yonemoto N @nyonenyone]

Risk Prediction in Cardio-Oncology: Conceptual and Methodological Considerations: JACC: CardioOncology State-of-the-Art Review | JACC: CardioOncology https://t.co/1RHleG9XRM

[American College of Cardiology @ACCinTouch]

ALLEVIATE-HF: #HeartFailure risk detection with an insertable cardiac monitor paired w/ a centrally coordinated nurse-led diuretic intervention was safe but did not reduce CV events in ambulatory patients w/ recent symptomatic HF events.

Learn more: https://t.co/yNqqKE2b5c #JACC

[HeartRhythm @hrs_journal]

Subcutaneous ICD Therapy in Patients with Monomorphic Ventricular Tachycardia: Arrhythmia Recurrence, Shock Rate, and Management Strategies

https://t.co/HHKXOrCeKk

[HeartRhythm @hrs_journal]

The present and the future of risk stratification for and prevention of sudden cardiac death: A Heart Rhythm Society think tank meeting

https://t.co/ylW85ojtAV

[Heart_BMJ @Heart_BMJ]

Cardiopulmonary exercise testing in contemporary cardiology: physiological insights, novel applications and evolving algorithms https://t.co/y6tTSsvc5V

[American College of Cardiology @ACCinTouch]

Circulating levels of micro- and nanoplastics were associated w/ structural plaque vulnerability in #cvACS, using optical coherence tomography, according to research published in #JACCIMG.

Get full details ➡️ https://t.co/vJfhSD7Ghq #CardioX

[Ahmed Elmorsy Mohamed @3absatar74]

Timely question in AF care: can semaglutide lower arrhythmia recurrence after ablation? In our Heart Rhythm time-to-event meta-analysis of 7,798 pts, semaglutide was linked to lower recurrence (HR 0.71; 95% CI 0.54–0.94). Promising, hypothesis-generating, needs RCTs.

[American College of Cardiology @ACCinTouch]

MAUDE Registry: Late pericardial effusion following LAAO device implantation was associated w/ negative patient outcomes, including mortality, suggesting the need for long-term surveillance of these patients.

Read more: https://t.co/rQF1GwJhg7 #JACCAdvances

[HeartRhythm @hrs_journal]

Percutaneous Stellate Ganglion Block in Left Ventricular Assist Device recipients with refractory electrical storm: Insights from the STAR registry

@s_savastano

https://t.co/X40zf5za1N

[Jorge Faerron @cardiopedhnn]

Stratified treatment of myocardial infarction w non-obstructive #coronary_arteries

https://t.co/U0DtQ4T9ib

[Ahmed Bennis MD 🫀 @drbennisahmed]

Optimal potassium range in HF = 4.2–5.0 mmol/L r

•HFrEF → Reverse J-shaped: hypokalemia is dramatically more dangerous. Risk spikes sharply below 4.0.

•HFpEF → Flat U-shaped: risk is more symmetric, lower overall mortality, less steep penalty for low K⁺

[javad mikaeili @javadm20]

More application; better results ; higher trade-off for complications! good news!#Epeeps

[Ahmed Bennis MD 🫀 @drbennisahmed]

Outcomes of Early Sodium-Glucose Cotransporter 2 Inhibitor Use in Takotsubo Syndrome

early sodium-glucose cotransporter-2 inhibitor use after Takotsubo syndrome was associated with lower all-cause mortality but not lower cardiovascular event rates.

https://t.co/TV4hLb5l4a

[TCTMD @TCTMD]

CONDUCT-AF: LBBAP a Good Option for ‘Pace and Ablate’ Strategy https://t.co/U6s3jobdcN

[JACC Journals @JACCJournals]

Ruvonoflast, an oral NLRP3 inhibitor, provides early, sustained, & reversible reductions in #hsCRP & significantly lowers inflammatory biomarkers IL-6 & fibrinogen in cardiometabolic patients with elevated #ASCVD risk https://t.co/HAQsOzox8i

#EASCongress2026 #JACC @ProfKausikRay

[TCTMD @TCTMD]

Using a self-expanding valve offers lower risk of bioprosthetic valve dysfunction and better hemodynamics for patients with severe symptomatic aortic stenosis and small annuli, according to new data from the SMART trial. https://t.co/krR4U9rAsF
#EuroPCR 2026

[Ahmed Bennis MD 🫀 @drbennisahmed]

New data from ORBITA: computed microvascular resistance (MVR) predicts who benefits from PCI.

Patients with HIGH MVR → attenuated benefit. Microvascular disease may be the reason PCI underperforms.

Bottom line: assess microvascular disease BEFORE stenting.

[Ahmed Bennis MD 🫀 @drbennisahmed]

Managing Post-AMI Ventricular Free-Wall Rupture (VFWR) — A decision algorithm every cardiologist should know!

The key question: Is the patient hemodynamically stable?

Every second counts in VFWR management. The Heart Team approach is essential!

#Cardiology #VFWR #HeartAttack